Home > FOXBusiness.com > Early-Market Movers: Human Genome Sciences, Ford

Early-Market Movers: Human Genome Sciences, Ford

By Michael Goldstein - November 02, 2009

provided by

Stock futures were pointing toward a positive opening after Ford posted a surprise profit for the third quarter.

Here are some of the early-market movers for Monday.

Human Genome Sciences Inc. (HGSI)

Shares were up 32.7% in pre-market trading after the company announced its experimental lupus drug Benlysta was showed successful results in a second large clinical trial. This could lead to approval of the first new treatment for Lupus in 50 years.

Kopin Corp. (KOPN)

The semiconductor product company beat the Street with third-quarter results reporting earnings per share of 13 cents per share on $32 million in revenue. Analysts were expecting earnings of 4 cents per share on revenue of $27.26 million. Kopin shares were up 12.6% in pre-market trading.

Vertex Pharmaceuticals (VRTX)

The company announced a trial of its Telaprevir hepatitis C treatment showed that twice-daily use was comparable to three-times a day. The change in dosage could increase patient convenience and present competitive advantage against other new therapies. Vertex shares were up 10.3% in pre-market trading.

Ford Motor Company (F)

Citing cost cuts, improved credit results and increased North American market share, Ford posted a surprise profit for the third quarter reporting earnings of 29 cents per share. Analysts had been expecting a loss of 12 cents per share and the stock was up 8.4% in pre-market trading.

Amylin Pharmaceuticals, Inc. (AMLN)

Shares were up 7.8% in pre-market trading Monday after announcing after the bell Friday it had entered into exclusive agreements with Takeda Pharmaceutical Company Limited to co-develop and commercialize obesity treatment drugs. Amylin will receive $75 million up-front and milestone payments could reach $1 billion.

GTx Inc (GTXI)

Shares dropped 29.3% after the company announced that the FDA did not approve its experimental drug Toremifene Citrateto for reducing fractures in men with prostate cancer and asked the company to conduct a second late-stage study.